Friday, February 14, 2020
Thermo Fisher Scientific, the world leader in serving science, and NanoPin Technologies, Inc., the developer of the novel NanoPin diagnostic platform for rapid and quantified results from patient blood samples, have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows.
Through the detection of disease-related antigens directly from patient blood samples, NanoPin's unique diagnostic platform using Thermo Fisher's advanced LC-MS technology will lead to the development of sensitive clinical assays for infectious disease. This will enable healthcare providers to reduce time to results, determine infection stage and monitor patient response to prescribed treatment. The quantified information gleaned from the combined technology will support clinical decision-making and the provision of personalized patient care unique to their disease state.
"Time is critical when it comes to the diagnosis and treatment of patients suffering from infectious disease, and current methods do not facilitate prompt diagnosis and rapid evaluation of treatment response," said Bradley Hart, senior director, clinical research, chromatography and mass spectrometry, Thermo Fisher Scientific.
Dr. Thomas Tombler, chief executive officer, NanoPin Technologies, said, "The current diagnostic solutions available for the detection and monitoring of infectious disease are not sufficient because they limit patient outcomes and the global management of such ailments. Through our agreement with Thermo Fisher, our unique diagnostic platform has the potential to change how infectious diseases, such as tuberculosis, are detected, treated and controlled by solving the unmet needs of healthcare providers managing patient care throughout the world."
